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Introduction
Achromatopsia (ACHM; also known as rod monochromatism) is an autosomal recessive form of  cone dys-
function that presents in infancy. It is characterized by reduction of  visual acuity, photophobia, nystagmus, 
and poor color vision (1, 2). To date, 6 genes have been found to cause ACHM: cyclic nucleotide-gated 
cation channel Β3 (CNGB3) (3), cyclic nucleotide-gated cation channel Α3 (CNGA3) (4), guanine nucleo-
tide-binding G(t) subunit Α2 (GNAT2) (5), cone cyclic GMP-specific 3′,5′ phosphodiesterase 6Α (PDE6C) 
(6), cone cyclic GMP-specific phosphodiesterase G (PDE6H) (7), and activating transcription factor 6 
(ATF6) (8). ATF6 is the most recent of  these disease genes to be identified (8–12), and, in contrast to other 
ACHM disease genes, it is not involved in the cone phototransduction pathway (13).
ATF6 encodes a glycosylated 670–amino acid type 2 ER transmembrane protein (14, 15). The ATF6 pro-
tein consists of a luminal ER stress–sensing domain coupled across the ER membrane to a cytosolic basic leu-
cine zipper (bZIP) domain transcription factor. It is an important regulator of the unfolded protein response 
(UPR), an intracellular signal transduction mechanism that prevents ER stress and ensures ER homeostasis 
(16). In response to ER stress, monomeric ATF6 protein migrates from the ER to the Golgi apparatus where it 
Achromatopsia (ACHM) is an autosomal recessive disease that results in severe visual loss. 
Symptoms of ACHM include impaired visual acuity, nystagmus, and photoaversion starting 
from infancy; furthermore, ACHM is associated with bilateral foveal hypoplasia and absent or 
severely reduced cone photoreceptor function on electroretinography. Here, we performed genetic 
sequencing in 3 patients from 2 families with ACHM, identifying and functionally characterizing 
2 mutations in the activating transcription factor 6 (ATF6) gene. We identified a homozygous 
deletion covering exons 8–14 of the ATF6 gene from 2 siblings from the same family. In another 
patient from a different family, we identified a heterozygous deletion covering exons 2 and 3 of 
the ATF6 gene found in trans with a previously identified ATF6 c.970C>T (p.Arg324Cys) ACHM 
disease allele. Recombinant ATF6 proteins bearing these exon deletions showed markedly impaired 
transcriptional activity by qPCR and RNA-Seq analysis compared with WT-ATF6. Finally, RNAscope 
revealed that ATF6 and the related ATF6B transcripts were expressed in cones as well as in all retinal 
layers in normal human retina. Overall, our data identify loss-of-function ATF6 disease alleles that 
cause human foveal disease.
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is cleaved in the transmembrane domain by Golgi-resident site 1 and site 2 proteases, releasing its cytosolic bZIP 
transcription factor domain (17, 18). The liberated ATF6 bZIP transcription factor domain then enters the nucle-
us and upregulates target genes that include ER chaperones, such as BiP/Grp78 and protein-folding enzymes 
(14, 19, 20). Thus, ATF6 signaling helps cells survive ER stress by increasing the cell’s protein-folding capability.
To date, 11 different ATF6 disease alleles have been identified in patients with ACHM (8, 9, 11, 12, 
21), containing missense, nonsense, and indel mutations or splice-site changes. In this paper, we identified 
and characterized 2 additional multiexon-spanning ATF6 disease alleles in patients with ACHM. Consis-
tent with prior analyses of  other ATF6 ACHM alleles, we found that recombinant ATF6 proteins with 
these large deletions show severely impaired transcriptional activity. The data support the hypothesis that 
intact ATF6 transcription factor function is necessary for cone photoreceptor function and survival (8, 21). 
Interestingly, we found, using the RNAscope assay, that ATF6 was expressed in cones and throughout the 
retinal layers. Thus, defects in ATF6 may also have an important role in visual processing of  the retina.
Results
Multiexon deletions in ATF6 found in patients with ACHM. Eleven ATF6 photoreceptor disease alleles have 
been previously identified in patients with ACHM or cone-rod dystrophy; these alleles contain single-nu-
cleotide changes (i.e., missense, nonsense, and splice site mutations), small deletions, or duplications that 
disrupt ATF6 production or function (Table 1) (8, 9, 11, 12, 21). In the current study, we identified 2 ATF6 
mutations that delete large fragments of  the ATF6 gene, leading to loss of  multiple exons (Table 1).
In 2 siblings from family A, we identified a homozygous deletion, c.909+1_1720-1del, that leads to the loss 
of  exons 8–14 (Table 1 and Figure 1A). The exact breakpoint is defined as NG_029773.1:g.58488_115797de-
linsAGAGCTC; NG_029773:1(ATF6_v001):c.1008_1719+13728delinsAGAGCTC. Segregation in both 
parents using breakpoint PCR analysis showed that both parents are heterozygous carriers of  the deletion 
(Figure 1A). In another patient from family B, we studied a heterozygous deletion, c.82+1_248-1del, that 
leads to the loss of  exons 2 and 3 (Table 1 and Figure 1A) (10). The patient has a second heterozygous 
mutation, c.970C>T;p.Arg324Cys, previously reported in other patients with ACHM (8). The parents sub-
sequently underwent genetic testing and were found to be heterozygous carriers of  either the previously 
characterized c.970C>T, (p.Arg324Cys) ATF6 allele or the c.82+1_248-1del ATF6 allele, respectively (Fig-
ure 1A). The parents from both families A and B had no visual defects. Furthermore, parents reported no 
consanguinity. At early infancy, all patients presented reduced visual acuity, nystagmus, and photophobia.
Both novel mutations (i.e., exons 8–14 deletion and exons 2–3 deletion) in ATF6 affect domains of  
the ATF6 transcriptional activity (Figure 1B). If  the deletion flanking exons are spliced directly onto each 
other, both deletions in the mRNA are in-frame. The exon 8–14 deletion removed 270 amino acid residues, 
including the bZIP domain, the transmembrane domain, and most of  the luminal domain of  ATF6 (Figure 
1B). When exons 2 and 3 were deleted, 55 amino acid residues were removed, leading to removal of  part of  
the transcriptional activator domain of  ATF6 (Figure 1B).
The patient with the c.82+1_248-1del ATF6 allele also carries a SNP in ATF6 (rs1058405) that intro-
duces a Met67Val amino acid change in the protein (Figure 1B, M67V). Methionine and valine are aliphat-
ic, nonreactive amino acids with similar molecular structures, suggesting that this conservative substitution 
is neither pathogenic to the ATF6 conformation nor detrimental to its function. Furthermore, this variant 
is widespread in the general population, with an allele frequency of  2.31 × 10–1 (https://gnomad.broadin-
stitute.org/gene/ENSG00000118217?dataset=gnomad_r2_1), making it unlikely to be a disease-causing 
variant. For comparison, the allele frequency of  the pathogenic c.970C>T;(p.Arg324Cys) ATF6 allele is 
2.13 × 10–5 (https://gnomad.broadinstitute.org/gene/ENSG00000118217?dataset=gnomad_r2_1). How-
ever, prior biochemical experiments reported functional differences for the M67V ATF6 variant (22).
Functional analysis of  ATF6 alleles with large multiexon deletions. To determine how deletion of  exons 8–14 
or exons 2–3 in ATF6 affects ATF6 function, and to experimentally determine whether the Met67Val ATF6 
variant causes pathogenic consequences for ATF6 function, we transfected HEK293 cells with FLAG-
tagged cytosolic domains of  WT-ATF6, the Met67Val variant of  ATF6 (ATF6[M67V]), an ACHM-linked 
N267* (ATF6[N267*]) (8, 21), ATF6[D28_T82del], and ATF6[I304-R573del] (Figure 2A). The WT-ATF6 
cytosolic domain served as the positive control and N267*, a previously identified ACHM-linked mutation 
that does not possess any ATF6 transcriptional activity, served as a negative control (21).
To determine the transcriptional activity on the ATF6 variants, we first investigated the protein 
expression levels of  BiP/GRP78 (one of  the most highly induced transcriptional targets of  ATF6, refs. 
3insight.jci.org   https://doi.org/10.1172/jci.insight.136041
R E S E A R C H  A R T I C L E
14, 23) by immunoblot analysis using antibodies against BiP/GRP78. The BiP/GRP78-immunoreactive 
band was present in all groups (Figure 2A). However, the intensity of  the BiP/GRP78-immunoreactive 
band was weak in all the groups except for WT-ATF6 and ATF6[M67V]. Next, we performed qRT-PCR 
analysis on these transfected samples and found that ATF6 variants encoding the ACHM-linked N267* 
ATF6[N267]*, ref. 8)], ATF6[D28_T82del], and ATF6[I304-R573del] failed to transcriptionally induce 
expression of  ATF6 target genes BiP/GRP78, HerpUD1, and Chop (24–26) (Figure 2B). By contrast, the 
mRNA levels of  BiP/GRP78, HerpUD1, and Chop were induced in WT-ATF6 and ATF6[M67V]. We did 
not observe changes in ERdj4 (a downstream target gene induced by the IRE1 signaling pathway) mRNA 
among the experimental groups
To further characterize the transcriptional activity of  these ATF6 variants, we examined a 17-gene 
panel of  ATF6 transcriptional targets, previously defined by RNA-Seq of  HEK293 cells expressing intact 
ATF6 transcriptional activator fragment (27). Strong induction of  ATF6 target genes by RNA-Seq was 
found in transfected HEK293 cells with WT-ATF6 or the Met67Val ATF6 variant (ATF6[M67V]) (Figure 
3, bottom 2 rows). Expression of  ATF6[N267*], ATF6[D28_T82del], and ATF6[I304-R573del] revealed 
no induction of  these ATF6 targets (Figure 3, top 3 rows). Our qRT-PCR and RNA-Seq analyses reveal that 
ATF6 transcriptional activity was lost in ATF6[N267*], ATF6[D28_T82del], and ATF6[I304-R573del] 
mutations, showing similarities to previously characterized ACHM-associated ATF6 variants (8).
Clinical findings in the patient with exons 2 and 3 of  the ATF6 gene deleted in this mutation. The patient with the 
deletion of  exons 2–3 in the ATF6 allele is a 7-year-old boy, who, starting in infancy, presents nystagmus, 
impaired visual acuity, and photophobia. Fundus examination demonstrated crowded optic discs in both 
eyes and mild macular atrophy (Figure 4A). Fundus autofluorescence imaging showed mild foveal hyperaut-
ofluorescence (Figure 4B). Spectral domain-optical coherence tomography showed severe foveal hypoplasia 
in the right (Figure 4C, top) and left (Figure 4C, bottom) eyes and focal disruption in the inner segment ellip-
soid layer at the site of  the presumed foveal pit (Figure 4C, arrowheads). In addition, the photopic full-field 
(light-adapted 3.0) electroretinogram (ERG) recordings showed defective (barely detectable) amplitudes for 
the a-wave and b-wave responses (Table 2) in the patient with the deletion of  exons 2–3 in ATF6. These find-
ings are consistent with prior imaging studies of  ATF6-associated patients with ACHM (10).
Expression of  ATF6 and ATF6B mRNA in human retina. ATF6 is a member of  the bZIP transcription 
factors and is encoded as 2 isoforms, ATF6 and ATF6B (8). Other ACHM disease genes are specifically 
expressed in cones and are all functional components of  the phototransduction cascade. To determine the 
localization and expression of  ATF6 and ATF6B in the human retina, and especially in the cones, we per-
formed triple-labeling experiments using RNA oligo probes specific for the mRNA of  human retinal cone 
arrestin-3 (Arr3), ATF6, and ATF6B in vertical cross sections of  the human adult retina. Human retinal 
Table 1. Summary of identified ATF6 disease alleles
Nucleotide change Effect Protein Reference
c.82+5G>T Splicing defect p.D28Gfs*36 8
c.353delC Truncation p.P118Lfs*31 8
c.355_356dupG Truncation p.E119Gfs*8 9
c.797dupC Truncation p.N267* 8
c.970C>T Point mutation p.R324C 8
c.1110dupA Truncation p.V371Sfs*3 8
c.1126C>T Truncation p.R376* 12
c.1187+5G>C Splicing defect p.N366Hfs*12 8




c.1691A>G Point mutation p.D564G 11
c.1699T>A Point mutation p.Y567N 8
c.909+1_1720-1del Exon 8–14 deletion p.I304_R573del Current study
c.82+1_248-1del Exon 2–3 deletion p.D28_T82del Current study
Two new multiexon deletion alleles of ATF6 were identified in patients. The nucleotide changes and molecular and 
protein effects of the nucleotide changes of the 2 new multiexon deletion alleles (red) and previously identified ATF6 
alleles are listed. Variants are presented with respect to ATF6 (RefSeq, NM_007348.3).
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Arr3 is a cone specific marker (28–30). Figure 5 shows an example of  a vertical section of  the midperiphery 
of  the human retina triple labeled with Arr3, ATF6, and ATF6B. In situ hybridization results showed that 
the mRNA probe for Arr3 is found in the cell bodies and outer segments of  cones; furthermore, mRNA 
probes for ATF6 and ATF6B are observed in all retinal layers. In a merged figure, ATF6 and ATF6B mRNA 
puncta were localized within the cell bodies that are labeled with Arr3 mRNA in the outer nuclear layer. 
In addition, ATF6 and ATF6B puncta were localized in the outer plexiform layer, inner nuclear layer, inner 
plexiform layer, and ganglion cell layer. Our data show that ATF6 was not only expressed in cones, but also 
widely expressed in all the retinal layers.
Discussion
ATF6 mutations have previously been found in patients with ACHM or cone-rod dystrophy and those 
patients carried single-nucleotide changes (i.e., missense, nonsense, and splice site mutations), small dele-
tions, and small duplications of  the gene (8, 9, 11, 12). These mutations lead to loss of  ATF6 function by 
damaging the amino-terminal transcriptional activator/bZIP DNA–binding domain of  ATF6 or impairing 
the carboxyl-terminal ER to Golgi intracellular protein trafficking domain of  ATF6 (8, 21). Here, we study 
two new larger genomic deletions of  ATF6 in 3 patients with ACHM that lead to multiexon deletions 
within ATF6. The deletion c.909+1_1720-1del in the ATF6 gene identified in the affected siblings removes 
the in-frame bZip, transmembrane, and luminal domains of  ATF6 (exon 8–14 deletion, p.I304_R573del, 
Figure 1B). The deletion c.82+1_248-1del in the ATF6 gene identified in the affected single patient removes 
an in-frame part of  the transcriptional activation domain (exons 2–3 deletion, p.D28_T82del, Figure 1B). 
The effect on ATF6 function in cells expressing these disease-causing variants was tested with recombinant 
ATF6[N267*] (8, 21), ATF6[D28_T82del], and ATF6[I304-R573del] ATF6 proteins. Our transcriptom-
ic analyses demonstrate that the ACHM-linked N267* and ATF6 variants, encoding p.D28_T82del and 
p.I304-R573del, show severely reduced induction of  ATF6 transcriptional target genes compared with the 
WT-ATF6 and ATF6[M67V] by qRT-PCR and by RNA-Seq. These findings demonstrate that both mul-
tiexon deletion ATF6 variants completely lose transcriptional activator function. These findings further 
underscore that all ACHM-linked ATF6 variants identified to date impair transcriptional activity.
The 2 isoforms of  ATF6 share significantly conserved bZIP domains and DNA-binding domains; how-
ever, the ATF6 isoform is better studied than ATF6B biochemically and physiologically (31–35). In the 
current study, we examined the expression of  both ATF6 and ATF6B mRNA by in situ hybridization in 
the human retina and RNAscope assay. The RNAscope assay is based on the branched DNA method 
described in previous studies (36–39). RNAscope in situ hybridization decreases nonspecific hybridization 
and increases signal amplification by using a Z probe, which has 25 bp of  oligonucleotides that are com-
plementary to a region of  the ATF6 and ATF6B mRNA. We observed ATF6 and ATF6B mRNA expression 
Figure 1. Pedigrees and topography of disease-causing mutations identified in the patients. (A) Pedigree drawings of patients with deletions of exons 
8–14 and exons 2–3 in ATF6. (B) The amino acid organization, protein topology, and functional domains of ATF6 are shown, and the positions of the ATF6 
variants are mapped onto the schematic drawing. Variants tested in this study are shown in red.
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Figure 2. Functional characterization of the ATF6 multiexon deletion variants. (A) HEK293 cells were transfect-
ed with plasmids encoding the cytosolic transcriptional activator domains of WT-ATF6, the M67V ATF6 variant 
(ATF6[M67V]), the ACHM-linked N267* ATF6 variant (ATF6[N267*]), the variant with deletion of exons 2–3 in ATF6 
(ATF6[D28_T82del]), or the variant with deletion of exons 8–14 in ATF6 (ATF6[I304_R573del]). Cell lysates were 
immunoblotted for recombinant ATF6 protein expression (anti-FLAG), BiP/Grp78 protein, and HSP90 (loading con-
trol). (See complete unedited blots in the supplemental material.) (B) The mRNA levels of ATF6 downstream target 
genes (BIP, HerpUD1, and Chop) and an XBP1 transcriptional target gene (ERdj4) were measured by real-time quanti-
tative PCR and normalized to mRNA levels in untransfected control samples. Data are shown as mean ± SEM; 3 sets 
of independent experiments were performed. Data in B were analyzed by 1-way ANOVA and showed significance at 
**P < 0.01; *** P < 0.001; ****P < 0.0001.
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on the cone photoreceptors and in all the retinal layers of  the human retina by RNAscope in situ hybridiza-
tion. The mRNA expression of  ATF6 and ATF6B described in the current study is consistent with previous-
ly performed immunohistochemistry studies in the mouse retina, which also show ATF6 expression in all 
the retinal layers (9, 12). Furthermore, several in vitro studies show that ATF6 expression in inner retinal 
cells (e.g., retinal ganglion cells) is induced after ER stress (40–42). Together with our current results, these 
findings suggest that ATF6 plays an essential role in regulating ER stress in all retinal neurons. The reasons 
why loss of  ATF6 preferentially causes a cone defect are unclear. One possibility is that other retinal cells 
have additional mechanisms for dealing with ER stress not found in cones. Another possibility is that cones 
undergo unique forms of  ER stress that specifically require ATF6 function.
In recent years, structurally distinct small molecules have been identified that can activate or inhib-
it ATF6 or other parallel signal transduction pathways of  the UPR to help cells tolerate ER stress (27, 
43–46). Our functional studies support that ATF6 mutations linked to retinal development disease arise 
from loss of  ATF6 transcriptional activity, and, in turn, this is caused by defects at distinct steps of  ATF6 
activation (8, 21). Based on these findings, ATF6-activating compounds may be helpful to correct the vision 
loss disease arising from ATF6 mutations in patients. In particular, in patients carrying loss-of-function 
ATF6 alleles arising from ER retention of  the ATF6 protein, the activator of  ATF6 (N-(2-hydroxy-5-meth-
ylphenyl)-3-phenylpropanamide [AA147]) (27), may be helpful to restore activity through promotion of  
ATF6 ER-to-Golgi trafficking. Alternatively, small molecules that induce UPR transcription factors with 
similar downstream transcriptional programs to ATF6, such as XBP1, may be helpful to compensate for 
loss of  ATF6 (27, 47).
Methods
Patients. Patients were clinically evaluated at 2 centers (Institute de la Vision, Paris, France, and Medical 
College of  Wisconsin). For RNAscope in situ hybridization, adult human eye samples were collected with 
appropriate consent from the San Diego Eye bank (product code V0180).
Clinical evaluation. Spectral-domain optical coherence tomography, fundus, and autofluorescence (Hei-
delberg Engineering) imaging were performed using standard methods using the Heidelberg Spectralis (8). 
Light-adaptation thresholds full-field ERG was performed on all patients using the International Society 
for Clinical Electrophysiology of  Vision standard protocols using JET disposable contact electrodes (48).
Genetic analysis and screening of  ATF6. The patient with the deletion of  exons 2–3 in ATF6 and his father 
underwent genetic testing using Retinal Dystrophy Panel Plus (Blueprint Genetics), which covers 266 genes 
known to cause inherited retinal diseases discovered by high-throughput sequencing and deletion/duplica-
tion analysis. The siblings with the deletion of  exons 8–14 in ATF6 underwent genetic testing at the Institute 
of  Ophthalmology, Tuebingen, Germany, by a step-wise procedure analyzing the genes known to be asso-
ciated with ACHM by PCR and Sanger sequencing as previously described (8). The exact breakpoint was 
Figure 3. The RNA-Seq analysis. The heatmap 
shows the log2 fold changes of 17 ATF6 target genes 
in the RNA-Seq analysis of HEK293 cells trans-
fected with WT-ATF6, ATF6[M67V], ATF6[N267*], 
ATF6[D27_T82del], and ATF6[[I304_R573del].
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defined by breakpoint PCR and Sanger sequencing.
Biochemical assays. The WT-ATF6(aa 1–373), ATF6[Met67Val(aa 1–373)], ATF6[N267*], and 
ATF6[D28_T82del] expression plasmids were generated by site-directed mutagenesis using the Quik-
Change II Site-Directed Mutagenesis Kit (Agilent Technologies Inc.) in the coding region of  FLAG-
tagged-ATF6(aa 373) pcDNA3.1 plasmid. The ATF6[I304-R573del] expression plasmid was generated 
in the coding region of  FLAG-tagged-ATF6(full-length) pcDNA3.1 as previously described (21). ATF6 
plasmids were transiently transfected into HEK293 cells, using Lipofectamine 2000 (Invitrogen). HEK293 
cells expressing WT or mutant ATF6 were lysed in SDS lysis buffer (2% SDS in PBS) and phosphatase 
inhibitor (Thermo Scientific). Protein concentrations of  the total cell lysates were determined by BCA pro-
tein assay (Pierce). Equal amounts of  protein were applied onto 4%–15% Mini-PROTEAN TGX precast 
gels (Bio-Rad) and analyzed by immunoblot. The following antibodies and dilutions were used: anti-FLAG 
at 1:5,000 (catalog A8592, MilliporeSigma), anti-BiP/GRP78 at 1:1,000 (catalog GTX113340, GeneTex 
Inc.), and anti-HSP90 at 1:5,000 (catalog GTX101448, GeneTex Inc.). After overnight incubation with 
primary antibody, membranes were washed in TBS with 0.1% Tween-20, followed by incubation of  a 
horseradish peroxidase–coupled secondary antibody (catalog 7074, Cell Signaling). Immunoreactivity was 
detected using the Super-Signal West chemiluminescent substrate (Pierce).
qRT-PCR analysis. HEK293 cells expressing WT and mutant ATF6 were lysed, and total RNA was 
collected using the RNeasy mini kit, according to manufacturer’s instructions (Qiagen). The mRNA 
was reverse-transcribed using the iScript cDNA Synthesis Kit (Bio-Rad). For quantitative PCR analysis, 
cDNA was used as template in SYBR Green qPCR Supermix (Bio-Rad). Primers used include human 
BIP/GRP78 (5′-GCCTGTATTTCTAGACCTGCC-3′ and 5′-TTCATCTTGCCAGCCAGTTG-3′), 
human HERPUD1 (5′-AACGGCATGTTTTGCATCTG-3′ and 5′-GGGGAAGAAAGGTTC-
CGAAG-3′), human CHOP (5′-ACCAAGGGAGAACCAGGAAACG-3′ and 5′-TCACCATTCG-
Figure 4. Clinical findings for the patient with deletion of exons 2 and 3 in ATF6. Fundus images of right and left 
eyes of the patient showed crowded optic discs and mild macular atrophy (A). Autofluorescence images of right and 
left eyes show mild hyperautofluorescence in fovea (B). Spectral domain OCT images showed foveal hypoplasia in right 
(top) and left (bottom) eyes (C). Inner segments and outer segments were disrupted at the fovea region (arrowheads).
Table 2. ERG recordings for the patient with deletion of exons 2–3 in ATF6
OD OS Normal
a-wave b-wave a-wave b-wave a-wave b-wave
Light-adapted 3.0 ERG
Amplitude (mV) –34.92 24.95 –33.76 25.2 –64.17 ± 38.03 178.8 ± 116.9
Implicit times (ms) 20 36 14 35 16.33 ± 1.56 27.5 ± 3.13
International Society for Clinical Electrophysiology of Vision standard ERG recordings for the patient with deletion of 
exons 2–3 and a healthy control individual. The full-field flash strength (in cd·s/m2) after light adaptation (photopic 
response) for the right eye (OD) and left eye (OS). The amplitude for a-wave and b-wave was not within the normal 
ranges under photopic condition in the patient.
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GTCAATCAGAGC-3′), human ERdj4 (5′-GGAAGGAGGAGCGCTAGGTC-3′ and 5′-ATCCT-
GCACCCTCCGACTAC-3′), human ATF6 (5′-GCTTTACATTCCTCCACCTCCTTG-3′ and 
5′-ATTTGAGCCCTGTTCCAGAGCAC-3′), and human total XBP1 (5′-GCAAGCGACAGCGCCT-3′ 
and 5′-TTTTCAGTTTCCTCCTCAGCG-3′). RPL19 mRNA levels (human RPL19, 5′-ATGTATCA-
CAGCCTGTACCTG-3′ and 5′-TTCTTGGTCTCTTCCTCCTTG-3′) served as internal normalization 
standards. The qPCR condition was 95°C for 5 minutes, 95°C for 10 seconds, 60°C for 10 seconds, and 
72°C for 10 seconds, with 40 cycles of  amplification.
RNA-Seq analysis. HEK293 cells expressing WT or mutant ATF6 were collected for RNA-Seq analysis. 
Cells were lysed and total RNA was collected using a Qiagen kit (RNeasy Mini Kit) in line with the man-
ufacturer’s recommendations and previous study (49). Three sets of  independent experiments were per-
formed. Briefly, conventional RNA-seq was conducted via BGI Americas on the BGI Proprietary platform, 
providing single-end 50-bp reads at 20 million reads per sample. Alignment of  sequencing data was done 
using DNAstar Lasergene SeqManPro to the GRCh37.p13 human genome reference assembly; assembly 
data were imported into ArrayStar 12.2 with QSeq (DNAStar Inc.) to quantify the gene expression levels 
and normalized to reads per kilobase per million (RPKM). Differential expression analysis and statistical 
significance calculations between different conditions were assessed using “DESeq” in R, compared with 
WT controls, with a standard negative binomial fit for the RPKM data. Heatmaps were generated using the 
log2 fold change data from this normalized differential expression analysis for genes of  interest.
RNAscope assay. In situ RNA hybridization was performed using the RNAscope assay (Advanced 
Cell Diagnostics) according to the manufacturer’s recommendations and previous study (38). Briefly, the 
anterior segment and crystalline lens were removed, and the eye cups were fixed with 4% paraformalde-
hyde and processed for cryostat sections (20 μm). The vertical sections were subjected to RNAscope Mul-
tiplex Fluorescent Assay. The sections were incubated with pretreatment 2 (RNAscope Target Retrieval 
Reagents, Advanced Cell Diagnostics) for 30 minutes at 40°C in a HybEZ oven (HybEZ Hybridization 
System, Advanced Cell Diagnostics), followed by pretreatment 3 (RNAscope ProteaseIII, Advanced 
Cell Diagnostics) containing protease for 30 minutes at 40°C. After pretreatment 3, the sections were 
washed with 5× deionized water and incubated with the prewarmed mRNA target probes (ATF6-C1, 
555291; Arr3-C2, 486461; or ATF6B-C3, 555301 [Advanced Cell Diagnostics]) for 2 hours at 40°C in 
the HybEZ oven. No-probe controls were performed in parallel (Supplemental Figure 1; supplemental 
material available online with this article; https://doi.org/10.1172/jci.insight.136041DS1). The sections 
were processed in wash buffer for 5 minutes and then incubated with Amp1 for 30 minutes at 40°C and 
washed with washing buffer for 5 minutes. The procedure was repeated for Amp2, Amp3, HRP-C1 
(Cy3), HRP-C2 (FITC), and HRP-C3 (Cy5). After washing with washing buffer for 5 minutes, the sec-
tions were coverslipped with Vectashield-DAPI mounting medium (Vector Laboratories). The images of  
sections were saved and processed with the Leica application suitex software under a Leica SP8 confocal 
microscopy and then were adjusted using Adobe Photoshop 7.0. Photoshop adjustments were carried 
out equally across sections. According to Advanced Cell Diagnostics, each mRNA molecule hybridized 
to a probe appears as separate small puncta.
Figure 5. Confocal micrographs of vertical sections of RNAscope in situ 
hybridization. Vertical section triple labeled with Arr3 (green), ATF6 (red), 
and ATF6B (white) mRNA in normal human retina. Nuclei were labeled with 
DAPI (blue) to identify the nuclear layers of the retina. The mRNA probe 
for Arr3 was found in the cell bodies and inner segments of cones, and the 
mRNA probes for ATF6 (red) and ATF6B (white) were observed in all the 
retinal layers. In the merged image, ATF6 and ATF6B mRNA puncta were 
localized within the cell bodies that are labeled with Arr3 in the outer nuclear 
layer (ONL). Three sets of independent experiments were performed (n = 2 
retinas). Expression of ATF6 and ATF6B puncta was localized in the ONL, 
outer plexiform layer (OPL), inner nuclear layer (INL), inner plexiform layer 
(IPL), and ganglion cell layer (GCL). Scale bar: 10 μm.
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Statistics. Data are expressed as mean ± SEM. Comparisons of  multiple groups were performed using 
1-way ANOVA. All in vitro studies were done with at least 3 sets of  independent experiments. GraphPad 
Prism was used for all analyses. A P value of  less than 0.05 was considered significant.
Study approval. This study was approved by the Institutional Review Boards of  UCSD, the Medical Col-
lege of  Wisconsin, the University Tuebingen, and Columbia University and conducted in accordance with 
the tenets of  the Declaration of  Helsinki and NIH guidelines. Patients and parents of  the patients provided 
informed consent for the study.
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